NCT04206254

GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Liver Cancer

GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Liver

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Cure&Sure Biotech Co., LTD · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This trial is to further study the safety and effectiveness of autologous gp96 treatment of liver cancer on the basis of preliminary work

Detailed description

RATIONALE: heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells. Overall Goals: \- to evaluate the safety and induction of anti-tumor immunity by administration of an immunogenic human tumor cell vaccine, and assess immune response in relation to clinical outcome. Primary Aim: \- to further evaluate effectiveness of autologous gp96 treatment of liver cancer on the basis of preliminary work. Secondary Aims: to study the immune response to vaccination, to monitor clinical responses , to further the safety of vaccine.

Conditions

• Liver Cancer

Interventions

Type	Name	Description
BIOLOGICAL	gp96	heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.

Timeline

• Start date: 2019-12-19
• Primary completion: 2022-08-05
• Completion: 2023-08-05
• First posted: 2019-12-20
• Last updated: 2019-12-20